TEACHERS ADVISORS, LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.

Quarter-by-quarter ownership
TEACHERS ADVISORS, LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q1 2019$5,737,000
+469.1%
470,987
+432.2%
0.01%
+600.0%
Q4 2018$1,008,000
-72.5%
88,492
-47.7%
0.00%
-50.0%
Q3 2018$3,672,000
+143.5%
169,260
+98.4%
0.00%0.0%
Q2 2018$1,508,000
-8.4%
85,328
+9.2%
0.00%0.0%
Q1 2018$1,646,000
+45.0%
78,174
-0.3%
0.00%
+100.0%
Q4 2017$1,135,000
+15.1%
78,406
+25.5%
0.00%0.0%
Q3 2017$986,000
+26.7%
62,494
-0.2%
0.00%0.0%
Q2 2017$778,000
-18.0%
62,615
+7.3%
0.00%0.0%
Q1 2017$949,000
-11.4%
58,377
-17.7%
0.00%
-50.0%
Q4 2016$1,071,000
-0.3%
70,948
+0.6%
0.00%0.0%
Q3 2016$1,074,000
-62.9%
70,505
-5.4%
0.00%
-60.0%
Q2 2016$2,893,000
+72.2%
74,530
+23.4%
0.01%
+66.7%
Q1 2016$1,680,000
-44.7%
60,415
+7.0%
0.00%
-50.0%
Q4 2015$3,038,000
+58.0%
56,484
+17.6%
0.01%
+50.0%
Q3 2015$1,923,000
+67.5%
48,034
+33.7%
0.00%
+100.0%
Q2 2015$1,148,000
+99.7%
35,925
+49.2%
0.00%
+100.0%
Q1 2015$575,000
+35.3%
24,0800.0%0.00%0.0%
Q4 2014$425,000
+28.8%
24,0800.0%0.00%0.0%
Q3 2014$330,000
-18.7%
24,0800.0%0.00%0.0%
Q2 2014$406,00024,0800.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2023
NameSharesValueWeighting ↓
TANG CAPITAL MANAGEMENT LLC 700,000$42,833,0008.57%
SILVERARC CAPITAL MANAGEMENT, LLC 308,819$18,897,0007.82%
Vahanian & Associates Financial Planning Inc. 45,533$2,786,0006.44%
DCF Advisers, LLC 238,500$14,594,0006.39%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 50,956$20,930,0004.72%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,531,923$93,738,0002.86%
Nicholas Investment Partners, LP 562,373$34,412,0002.45%
Bellevue Group AG 3,429,619$209,859,0002.44%
WASATCH ADVISORS LP 7,477,868$457,571,0002.25%
Quantum Private Wealth, LLC 73,772$4,514,0001.95%
View complete list of INTRA CELLULAR THERAPIES INC shareholders